CRISPR and Cas Gene Global Research Report 2024 | Now Available
01 août 2024 06h10 HE
|
Research and Markets
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Gene Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The crispr and cas gene market size has...
Gene Therapy in Rare Diseases Therapeutics Pipeline Report 2024: Analytical Perspective, Current Treatment Patterns, Collaborations, Licensing, Acquisitions
01 août 2024 04h02 HE
|
Research and Markets
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The "Gene therapy in Rare Diseases - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.Gene therapy in Rare...
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
31 juil. 2024 21h15 HE
|
Ocugen
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and...
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
31 juil. 2024 16h15 HE
|
Ocugen
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and...
Global Gene Therapy Strategic Research Report 2024-2030: Availability of Novel Therapies Drive Market Growth
31 juil. 2024 04h29 HE
|
Research and Markets
Dublin, July 31, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Gene Therapy is...
Hemophilia Patient Receives FDA Approved Gene Therapy Treatment Likely To Eliminate The Need For Preventative Factor Replacement
31 juil. 2024 04h00 HE
|
Cure 4 The Kids Foundation
LAS VEGAS, July 31, 2024 (GLOBE NEWSWIRE) -- Cure 4 The Kids Foundation (C4K) announced it has completed Nevada’s first successful infusion of Hemgenix®, a gene therapy option for adult patients...
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
30 juil. 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
29 juil. 2024 07h02 HE
|
Ocugen
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
25 juil. 2024 06h30 HE
|
Ocugen
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering,...
Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights
24 juil. 2024 09h56 HE
|
Spherix Global Insights
EXTON, PA., June 20, 2024, July 24, 2024 (GLOBE NEWSWIRE) -- The American Society of Retinal Specialists (ASRS) annual meeting held last week in Stockholm, Sweden, showcased groundbreaking...